[1] |
Jemal A, Siegel R, Ward E. Cancer statistics, 2010[J]. CA Cancer J Clin,2010,60(5):277–300.
|
[2] |
Mohagheqh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques[J].Radiographics, 2012, 32(6):1751–1773.
|
[3] |
Lutz AM, Willmann JK, Drescher CW,et al. Early diagnosis of ovarian carcinoma:is a solution in sight? [J].Radiology, 2011,259(2):329–345.
|
[4] |
Bharwani N, Reznek RH, Rockall AG. Ovarian cancer management: the role of imaging and diagnostic challenges[J]. Eur J Radiol,2011,78(1):41–51.
|
[5] |
Huchon C, Metzqer U, Bats AS,et al. Value of three-dimensional contrast-enhanced power Doppler ultrasound for characterizing adnexal masses[J]. J Obstet Gynaecol Res,2012,38(5):832–840.
|
[6] |
Gatreh-Samani F, Tarzamni MK, Olad-Sahebmadarek E, et al. Accuracy of 64-multidetector computed tomography in diagnosis of adnexal tumors[J]. J Ovarian Res, 2011, 4(1):15.
|
[7] |
Medeiros LR, Freitas LB,Rosa DD, et al. Accuracy of magnetic resonance in ovarian tumor:a systematic quantitative review[J]. Am J Obstet Gynecol, 2011,204(1):67,e1-e10.
|
[8] |
Thomassin-Naggara I, Balvay D, Aubert E, et al. Quantitative dynamic contrast-enhanced MR imaging analysis of complex adnexal masses: a preliminary study[J]. Eur Radiol,2012,22(4):738–745.
|
[9] |
Li W, Chu C, Cui Y, et al. Diffusion-weighted MRI: a useful technique to discriminate benign versus malignant ovarian surface epithelial tumors with solid and cystic components[J]. Abdom Imaging,2012,37(5):897–903.
|
[10] |
Kitajima K, Suzuki K, Senda M, et al. FDG-PET/CT for diagnosis of primary ovarian cancer[J]. NucI Med Commun, 2011,32(7):549–553.
|
[11] |
Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer:correlation between PET/CT,Doppler US, and CT or MRI[J]. Gynecol Oncol, 2010,116(3):389–394.
|
[12] |
Kitajima K, Murakami K, Sakamoto S, et al. Present and future of FDG-PET/CT in ovarian cancer[J]. Ann Nucl Med,2011,25(3):155–164.
|
[13] |
Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer[J]. Gynecol Oncol, 2014, 133(3):401–404.
|
[14] |
Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet, 2014,124(1):1–5.
|
[15] |
杨华,郎景和. 欧洲肿瘤内科协会对非上皮性卵巢癌的诊断、治疗和随访所制定的临床实践指南[J]. 国际妇产科学杂志,2011,38(4):339–342.
|
[16] |
Moyle P, Addlev HC, Sala E. Radiological staging of ovarian carcinoma[J]. Semin Ultrasound CT MR,2010,31(5):388–398.
|
[17] |
Forstner R, Sala E, Kinkel K, et al. ESUR guidelines: ovarian cancer staging and follow-up[J]. Eur Radiol,2010,20(12):2773–2780.
|
[18] |
Moyle P, Addley HC, Sala E. Radiological staging of ovarian carcinoma[J].Semin Ultrasound CT MR, 2010,31(5):388–398.
|
[19] |
Bharwani N, Reznek RH, Rockall AG.. Ovarian cancer management: the role of imaging and diagnostic challenges[J]. Eur J Radiol, 2011,78(1):41–51.
|
[20] |
Metser U, Jones C, Jacks LM, et al. Identification and quantification of peritoneal metastases in patients with ovarian cancer with multidetector computed tomography correlation with surgery and surgical outcome[J]. Int Gynecol Cancer,2011,21(8):1391–1398.
|
[21] |
Sala E, Rockall AG, Freeman SJ, et al. The added role of MR imaging in treatment stratification of patients with gynecologic malignancies:what the radiologist needs to know[J]. Radiology,2013,266(3):717–740.
|
[22] |
Lew A, Medjhoul A, Caramella C, et al. Interest of diffusion-weighted echo-planar MR imaging and apparent diffusion coefficient mapping in gynecological malignancies: a review[J]. J Magn Reson Imaging,2011,33(5):1020–1027.
|
[23] |
王春美,张孟超,刘云霞. 磁共振弥散加权成像在卵巢癌腹膜转移中的应用[J]. 实用妇产科杂志,2012,28(3):180–182.
|
[24] |
Lee HJ, Luci JJ, Tantawy MN, et al. Detecting peritoneal dissemination of ovarian cancer in mice by DWIBS[J]. Magn Reson Imaging,2013,31(2):227–234.
|
[25] |
宋金国,张红霞. 弥散加权背景抑制成像在卵巢癌分期的应用探讨[J]. 中国现代医生,2010,48(1):60–61.
|
[26] |
Fuccio C, Castellucci P, Marzola MC, et al. Noninvasive and invasive staging of ovarian cancer review of the literature[J].Clin Nuce Med,2011,36(10):889–893.
|
[27] |
Yuan Y, Gu ZX, Tao XF, et al. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a Meta-analysis[J]. Eur J Radiol,2012,81(5):1002–1006.
|
[28] |
Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer[J]. Crit Rev Oncol Hematol,2009,71(1):43–52.
|
[29] |
Gu P, Pan LL, Wu SQ, et al. CA125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma:a systematic review and Meta-analysis[J]. Eur J Radiol, 2009,71(2):164–174.
|
[30] |
Antunovic L, Cimitan M, Borsatti E, et al. Revisiting the clinical value of 18F-FDG PET/CT in detection of recurrent epithelial ovarian carcinomas[J]. Clin Nucl Med,2012, 37(2):e184–e188.
|
[31] |
葛海云,蒋创. 18F-FDG PET/CT在卵巢癌术后复发、转移监测中的应用[J]. 南京医科大学学报,2010,30(8):1203–1205.
|
[32] |
Wang L, Neoh KG, Kang ET, et al. Multifunctional polyglycerol-grafted Fe3O4 & SiO2 nanoparticles for targeting ovarian cancer cells[J]. Biomaterials,2011,32(8):2166–2173.
|
[33] |
Sukerkar PA, MacRenaris KW, Townsend TR, et al. Synthesis and biological evaluation of water-soluble progesterone-conjugated probes for magnetic resonance imaging of hormone related cancers[J]. Bioconiug Chem,2011,22(11):2304–2316.
|